Clinical Evaluation of the Vital Signs Monitoring System (VSMS)

June 29, 2017 updated by: G Medical Innovations Ltd.
This is an observational, cohort-based, single-site, prospective study conducted in accordance with ISO 14155-1:2003 and ISO 14155-1:2011. The primary objectives are to evaluate the accuracy of the device's measurements/readings in comparison to a gold standard or standard of care patient monitor.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This is an observational, cohort-based, single-site, prospective clinical study enrolling up to 100 patients who are hospitalized in the internal ward. There is no control group.

The primary objectives of the study are:

  1. Evaluate the body temperature measured by the ear unit and validate its accuracy.
  2. Evaluate the accuracy of SPO2 signals and results by comparing the readings to a gold standard device with a finger sensor.
  3. Evaluate the ECG and respiration signals recorded by the patch device by comparing them to the signals recorded by a patient monitor with standard leads.

    The secondary objectives of the study are:

  4. Usability - evaluate the ease of use of the device by medical staff and patients (e.g., positioning, activation, replacement of patch, understanding processes and requirements).
  5. Evaluate the signals quality and the patch adherence after 5 - 7 days on the chest.

The study will assess the safety and effectiveness of the Vital Signs Monitoring System (VSMS) for its intended use/proposed indications. Data will be collected while the VSMS is adhered to each patient for the entire hospitalization period, up to 7 days. There is no follow-up required.

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • P.O. Beer Ya'akov, Zerifin, Israel, 70300
        • Recruiting
        • Internal Ward B, Aliza Begin Building, Assaf Harofe Hospital (2nd Floor)
        • Contact:
        • Contact:
          • Peter Spiegel

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Hospitalized patients of both genders, above 18 years of age, with ASA physical status classified as 1-4. In order to obtain the necessary results, the following shall also define the patient population:

Temperature: 30-50% of subjects shall be febrile, i.e., having:

  • An elevated core or rectal temperature of 38.0°C or higher as measured by a clinical thermometer.
  • An elevated sublingual temperature of 37.5°C or higher as measured by a clinical thermometer.
  • An elevated Axillary temperature of 37.2°C or higher as measured by a clinical thermometer.

SPO2: 10-20% of patients shall have a blood oxygen saturation level of 70-90%.

ECG / Respiration: At least 20% of patients shall have some type of arrhythmia.

Description

Inclusion Criteria:

  • Signed written informed consent
  • Age above 18 years from both genders
  • American Society of Anesthesiologists (ASA) physical status classification of 1-4
  • Hospitalized in internal ward

Exclusion Criteria:

  • Abuse of alcohol or illicit drugs
  • History of mental retardation or any mental disease
  • Skin irritation / Atopic dermatitis or any other skin condition in the area of patient's upper chest that might affect his/her ability to adhere the device appropriately

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
VSMS with ear unit
application of Vital Signs Monitoring System with ear unit for 6-10 days during hospitalization (throughout their admission period)
The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
VSMS without ear unit
application of Vital Signs Monitoring System without ear unit for 6-10 days during hospitalization (throughout their admission period)
The VSMS will be adhered to each enrolled patient for the entire hospitalization period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Skin Temperature measured in units of Celsius/Fahrenheit
Time Frame: 6-10 days
Validation of measurement accuracy of skin temperature as compared to gold standard.
6-10 days
Oxygen Saturation measured in units of percentage peripheral saturated oxygen
Time Frame: 6-10 days
Validation of measurement accuracy of peripheral oxygen saturation as compared to gold standard.
6-10 days
.ECG signal recording and Respiration measured in units heart beat per minute
Time Frame: 6-10 days
Assess quality of device's recorded ECG and respiration signals as compared to patient monitor with standard leads
6-10 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of recorded signal
Time Frame: after 5-7 days of device usage
Evaluate the quality of recorded signals in time by comparing signal of day 1 with signal in last day of adherence of the patch
after 5-7 days of device usage

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Moshe Tishler, Professor, Assaf Harofeh Hospital/Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 25, 2017

Primary Completion (ANTICIPATED)

July 31, 2017

Study Completion (ANTICIPATED)

July 31, 2017

Study Registration Dates

First Submitted

June 15, 2017

First Submitted That Met QC Criteria

June 29, 2017

First Posted (ACTUAL)

July 2, 2017

Study Record Updates

Last Update Posted (ACTUAL)

July 2, 2017

Last Update Submitted That Met QC Criteria

June 29, 2017

Last Verified

June 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • CLN-7.4.7.10.20

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Respiration

Clinical Trials on Vital Signs Monitoring System

Search Similar Trials